Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge

Hvivo17 enrolled

Overview

A GMP rhinovirus was manufactured according to GMP and then characterised in human volunteers in the human viral challenge model.

Human Rhinovirus infection is an important precursor to asthma and chronic obstructive pulmonary disease exacerbations and the Human Viral Challenge model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new HRV-16 challenge virus produced specifically for this purpose. An HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer (University of Virginia Children's Hospital, USA) was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 cell line under Good Manufacturing Practice conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we conducted an initial safety and pathogenicity clinical study in adult volunteers in our dedicated clinical quarantine facility in London.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Rhinovirus

Interventions

Titre 1OTHER

Virus infection

Titre 2OTHER

Virus infection

Titre 3OTHER

Virus infection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Young healthy adults as determined by medical history, physical examination, serology (HIV and Hepatitis B and C) and clinical laboratory tests. * Female subjects were required to provide of a history of reliable contraceptive practice. Exclusion Criteria:included; * asthma, * hypersensitivity to mercurials or chicken eggs, * anatomic or neurologic abnormality impairing the gag reflex or contributing to aspiration, chronic nasopharyngeal complaints, * abnormal electrocardiogram (ECG), * febrile illness or significant symptoms of upper respiratory infection on the day of * Subjects using medication or other products for rhinitis or nasal congestion, * Subject who had received systemic glucocorticoids within 1 month, or cytotoxic or immunosuppressive drugs within 6 months of the study start. * Subjects agreed not to smoke during the quarantine phase.

Outcomes

Primary Outcomes

Virus shedding defined as area under the curve

Time frame: 10 days

Secondary Outcomes

Symptoms of respiratory tract infection

Time frame: 10 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.